PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New biologic aims to stabilize platelet counts in ITP patients
Disease control OngoingThis phase 3 trial tests whether adding ianalumab (a biologic drug) to standard corticosteroids helps adults with newly diagnosed immune thrombocytopenia (ITP) achieve a stable platelet response off all treatments at 12 months. About 226 participants will receive either ianalumab…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for ITP patients: experimental drug aims to boost platelets
Disease control OngoingThis phase 2 trial tests an experimental drug called ianalumab in 41 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants have already tried steroids and another standard treatment. The study mea…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC